HomeAI · summaries
Storia in 3 fonti
ADA: Amgen highlights Repatha perks, GLP-1 pitfalls in push to boost cardiometabolic pedigree
As Amgen strives to become the industry’s top player in cardiometabolic risk reduction by the start of the next decade, the company took to the American Diabetes Association 2026 Scientific Session | As Amgen strives to become the top player in cardiometabolic risk reduction by the start of the next decade, the company took to the American Diabetes Association 2026 Scientific Sessions in New Orleans this past weekend to bolster the case for its cholesterol-lowering blockbuster Repatha in a high-risk patient subgroup.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
- ·
biopharmadive.com
ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option
At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.
